Burkhard Gess

Dr. Burkhard Gess

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2017 in Science Signaling
Verified
Journal Article
Closed access
PDF file
CPCamila C. Portugal
Camila C. Portugal
RSRenato Socodato
Renato Socodato
TCTeresa Canedo
Teresa Canedo
CSCátia M. Silva
Cátia M. Silva
TMTânia Martins
Tânia Martins
JRJoao Relvas
Joao Relvas
Vitamin C is essential for the development and function of the central nervous system (CNS). The plasma membrane sodium–vitamin C cotransporter 2 (SVCT2) is the primary mediator of vitamin C uptake in neurons. SVCT2 specifically transports ascorbate, the reduced form of vitamin C, which acts as a reducing agent. We demonstrated that ascorbate uptake through SVCT2 was critical for the homeostasis of microglia, the resident myeloid cells of the CNS that are essential for proper functioning of the nervous tissue. We found that depletion of SVCT2 from the plasma membrane triggered a proinflammatory phenotype in microglia and resulted in microglia activation. Src-mediated phosphorylation of caveolin-1 on Tyr14 in microglia induced the internalization of SVCT2. Ascorbate treatment, SVCT2 overexpression, or blocking SVCT2 internalization prevented the activation of microglia. Overall, our work demonstrates the importance of the ascorbate transport system for microglial homeostasis and hints that dysregulation of ascorbate transport might play a role in neurological disorders.

1 August 2013 in Neuromuscular Disorders
Verified
Journal Article
Closed access
BGBurkhard Gess
Burkhard Gess
ASAnja Schirmacher
Anja Schirmacher
MBMatthias Boentert
Matthias Boentert
PYPeter Young
Peter Young

11 December 2015 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
BGBurkhard Gess
Burkhard Gess
JBJonathan Baets
Jonathan Baets
PJPeter De Jonghe
Peter De Jonghe
MRMary M Reilly
Mary M Reilly
DPDavide Pareyson
Davide Pareyson
PYPeter Young
Peter Young

29 April 2017 in Glia
Verified
Journal Article
Closed access
PDF file
DRDominik Röhr
Dominik Röhr
HHHartmut Halfter
Hartmut Halfter
JSJörg B. Schulz
Jörg B. Schulz
PYPeter Young
Peter Young
BGBurkhard Gess
Burkhard Gess

1 February 2015 in Experimental Neurology
Verified
Journal Article
Closed access
BGBurkhard Gess
Burkhard Gess
DRD. Röhr
D. Röhr
ELE. Lange
E. Lange
HHH. Halfter
H. Halfter
PYP. Young
P. Young

7 May 2015 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MSMones Saleh
Mones Saleh
BGBurkhard Gess
Burkhard Gess
BBBordignon Benoit
Bordignon Benoit
AAAlexandre Altié
Alexandre Altié
YPYoung Peter
Young Peter
Michel  FontésMichel Fontés
Michel Fontés
We previously described that fibroblasts from animal models of CMTX1 present genomic instability and poor connexon activity. In vivo, these transgenic mice present motor deficits. This phenotype could be significantly reverted by treatment with (CamKII) inhibitors. The objective of this study is to translate our findings to patients. We cultured fibroblasts from skin biopsies of CMTX1 patients and analyzed cells for genomic instabilty, connexon activity, and potential correction by CamKII inhibitors. The phenotypic analysis of these cells confirmed strong similarities between the GJB1 transgenic mouse cell lines and CMTX1 patient fibroblast cell lines. Both present mitotic anomalies, centrosome overduplication, and connexon activity deficit. This phenotype is corrected by CamKII inhibitors. Our data demonstrate that fibroblasts from CMTX1 patients present a phenotype similar to transgenic lines that can be corrected by CamKII inhibitors. This presents a track to develop therapeutic strategies for CMTX1 treatment.